Johnson & Johnson (JNJ) on Friday presented new data on IMAAVY, nipocalimab-aahu, its treatment for generalized myasthenia gravis, a chronic autoimmune disease that causes muscle weakness, across 12 abstracts at the European Academy of Neurology 2026 Congress.
Data from the Vivacity-MG3 trial showed patients who received IMAAVY alongside standard care early in their disease saw greater symptom reductions versus placebo at week 24 (-4.9 vs. -2.7), with more patients achieving sustained clinical improvement lasting 20 or more weeks, the company said.
Patients with less severe disease at baseline showed similar benefit (-4.5 vs. -2.3). Serious adverse events were lower in the IMAAVY arm than placebo (9% vs. 14%), according to the company.
IMAAVY is approved by the FDA and European Medicines Agency for adults and patients aged 12 and older with antibody-positive gMG, Johnson & Johnson said.
Price: $253.67, Change: $+8.79, Percent Change: +3.59%